Printer Friendly

LOUIS FERNANDEZ, PH.D., JOINS ARCTURUS PHARMACEUTICAL CORPORATION BOARD OF DIRECTORS

 WOBURN, Mass., May 27 /PRNewswire/ -- Arcturus Pharmaceutical Corporation announced today that Louis Fernandez, Ph.D., has joined the company's board of directors. Fernandez is retired president, chief executive officer and chairman of the board of directors of Celgene Corporation. He joined Celgene after a distinguished career at Monsanto Company where he most recently served as chairman of the board of directors.
 "Dr. Fernandez brings to Arcturus a wealth of expertise and strategic insight from his senior management experience both in leading industrial and emerging biotechnology companies," said Rex Bright, Arcturus president and CEO. "We look forward to his guidance as we continue to build Arcturus into a leading dermatology company."
 Fernandez began his 37 year career with Monsanto in 1949, joining as a chemist and rising to a variety of senior management level positions. He was appointed to the board of directors in 1971, serving as chairman from 1983 until his retirement from the company in 1986. Fernandez currently serves as chairman of the board of directors of Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharmaceuticals, Inc. He is a director of Alteon, Inc., A.G. Edwards, Inc., IMCERA Group Inc., and the Petrolite Corporation.
 Arcturus was established in 1991 to use advances in skin biology to develop and commercialize clinically superior products for dermatologic disorders. The company's proprietary drug delivery technology enhances penetration and retention of therapeutic compounds into the skin. Products in development currently include topical therapies for psoriasis and other immunologically mediated disorders such as atopic dermatitis; an anesthetic for cutaneous surgical procedures; and an antipruritic (anti-itch) product.
 -0- 5/27/93
 /CONTACT: Rex Bright, president and CEO, Arcturus Pharmaceutical Corp., 617-938-1686; Robert Gottlieb, senior vice president, Feinstein Partners Inc., 617-577-8110, for Arcturus/


CO: Arcturus Pharmaceutical Corporation ST: Massachusetts IN: MTC SU: PER

DJ -- NE001 -- 2776 05/27/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Words:304
Previous Article:LASERMASTER TECHNOLOGIES, INC. ANNOUNCES 'BIG COLOR' UPGRADE FOR HEWLETT PACKARD ENGINEERING PLOTTER
Next Article:HITACHI POSTS LOWER SALES AND PROFITS
Topics:


Related Articles
GENERAL SIGNAL ELECTS KOGAN, PRESIDENT OF SCHERING-PLOUGH, TO ITS BOARD
GARNIER ELECTED TO SMITHKLINE BEECHAM BOARD
IVAX ANNOUNCES RESULTS OF ANNUAL MEETING AND PROMOTION OF DR. JOHN K. WHISNANT
ARCTURUS PHARMACEUTICAL CORPORATION NAMES RICHARD J. SHARPE, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER
ANDRX ANNOUNCES EXECUTIVE APPOINTMENT
MONSANTO EXECUTIVE NAMED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF PHARMA MAR S.A., LEADING SPANISH BIOTECHNOLOGY AND DRUG DEVELOPMENT COMPANY
ARGONEX, INC., BIOPHARMACEUTICAL COMPANY RESULTING FROM ARGUS/TRIPLEX/ONCOLOGIX MERGER, APPOINTS SENIOR MANAGEMENT TEAM
SUNPHARM ESTABLISHES PHARMACEUTICAL ADVISORY BOARD
XENOVA APPOINTS TWO EXECUTIVES TO THE BOARD STRENGTHENS COMPANY'S DIVISIONALIZATION
Francis P. Tally, M.D., Appointed to Therion Biologics Board of Directors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters